Quick answer: Texas is a fault-based auto state with no mandatory no-fault benefit — PIP is optional coverage most drivers decline. So while a Florida imaging center collects the first dollars on a crash patient through the statutory $10,000 PIP benefit within months, a Texas center scanning the same patient has essentially two paths to cash: carry a Letter of Protection until the underlying case settles (often 1–3 years), or monetize the receivable early through a medical funding company at a meaningful discount to face value. That single structural difference reshapes everything downstream — DSO, working capital, revenue recognition, lender treatment, and what a buyer will pay for the business.

LOP Economics in Texas: Why Imaging A/R Works Differently Than Florida

Put the same personal-injury MRI in two different states and you get two different businesses.

In Florida, the no-fault statute routes the first $10,000 of the patient's medical benefits through PIP — statutory, adjudicated, and typically collected inside a few months, with the Letter of Protection picking up only what runs past the cap. In Texas there is no mandatory PIP layer at all. The state runs on fault: the money ultimately comes from the at-fault party's liability coverage, and that money doesn't move until the case resolves.

For an imaging center, that means Texas PI volume is LOP-dominant by construction. The attorney-driven receivable isn't the tail of the book the way it is in South Florida — it is the book. And a business whose largest asset is a portfolio of contingent legal claims needs its finance function built accordingly.

Key Takeaway: Florida PI imaging is a hybrid payer stack (statutory PIP first dollars + LOP tail). Texas PI imaging is a single-rail system: LOP paper resolving on litigation timelines, with medical funding companies offering early liquidity at a discount. The four consequences that follow — a longer and lumpier cash cycle, a funder-vs-holder portfolio decision on every case, revenue that must be booked at expected value rather than face, and QoE scrutiny of funding cash at exit — are structural. They don't respond to "work the aging harder." They respond to instrumentation.

The Structural Map: Florida vs Texas

Two implications hide in that table.

First, Texas centers carry more months of A/R at the same revenue. The LOP class alone benchmarks at 270–540 days of DSO on a yield-adjusted basis (the framework is in our imaging DSO benchmarks); a Texas center with heavy PI mix has most of its book on that clock, with no statutory fast layer blending the average down. Growth makes it worse before it makes it better: every new month of PI scanning adds working capital the settlement pipeline won't return for a year or more. If revenue is rising while the bank account tightens, that's not mismanagement — it's the conversion-cycle math of an LOP-dominant book, and it should be forecast, not discovered.

Second, someone will offer to solve this for you — at a price. That's the funding market.

Medical Funding Companies: Pipe or Counterparty?

In the Texas PI ecosystem, medical receivable funding companies sit between providers and settlements. The provider delivers the scan, and rather than waiting out the case, sells or borrows against the receivable; the funder advances a fraction of face value today and captures its margin when the case pays.

The accounting question that matters — and the one we find unexamined at most centers — is whether a given arrangement is a sale of the receivable or a financing secured by it:

• True sale (non-recourse): the funder owns the outcome. Your revenue on that scan is, economically, the discounted purchase price — full stop. Booking face-value revenue and treating the discount as a vague "adjustment" overstates what the business earns.
• Financing (recourse): you still own the receivable and the settlement risk; the funder's advance is a liability, not revenue. Cash arriving from a funder is a draw on a credit facility wearing a clinical gown.

The distinction sounds academic until you see books where every funder wire lands as revenue and the balance sheet shows no funding liability and no receivable portfolio at all. The P&L looks clean; the economics are invisible. Contract terms — advance rates, floors, recourse triggers, servicing obligations — differ meaningfully across funders, and the portfolio decision (which paper do we hold to settlement, which do we monetize, at what discount does holding beat selling) is one of the highest-leverage financial decisions a Texas PI-heavy operator makes. Most make it case by case, by habit, with no yield model. (The expected-value framework in LOP Economics: Real Yield vs Face Value is the starting point.)

What This Does to Your Books

Three accounting consequences follow directly from the structure:

1. Revenue belongs at expected value, not face. Under ASC 606 you recognize what you expect to be entitled to collect — for LOP paper, that's the yield-adjusted number, not the chargemaster. A Texas center booking gross LOP face as revenue is building an overstatement that some future auditor, lender, or buyer will unwind on their terms rather than yours.

2. Net collection rate must be measured by cohort. Monthly collections divided by monthly charges is meaningless when cash lags service by 12–30 months. Date-of-service cohort curves — what percentage of expected value has each vintage collected by month 6, 12, 24 — are the only honest instrumentation for an LOP-dominant book. (The method is in our net collection rate guide.)

3. Concentration is a balance-sheet risk, not a sales stat. When the book is attorney paper, exposure concentrates by law firm and by funder. Three firms controlling half your receivable is a credit posture no one chose on purpose — it should be measured monthly, like any lender measures obligor concentration.

What Lenders and Buyers Do With All This

A Texas imaging center's A/R gets marked twice by outsiders.

Lenders advance against imaging A/R with class-by-class haircuts, and LOP paper takes the deepest cut — banks that misread an aging report full of attorney receivables either walk or overcorrect (how banks misread imaging A/R covers the mechanics). A center that shows up with cohort curves and yield history borrows against the same book on materially better terms than one that shows up with an aging summary.

Buyers — and imaging centers sell on EBITDA multiples — send quality-of-earnings teams that normalize funding-company cash out of operating earnings and restate LOP revenue to realized yield. If your reported EBITDA quietly includes face-value LOP revenue or funder advances, the QoE process re-prices the business downward at the worst possible moment. Operators who intend to sell within five years should run their books the way the buyer's diligence team will — starting now, because what buyers actually pay is a function of what they can verify.

The 90-Day Instrumentation List

1. Classify every funding relationship as sale or financing based on the actual contract terms — recourse, advance rate, servicing — and book it accordingly.
2. Build the LOP cohort grid: date-of-service month × collection month, at expected value. Two hours of setup; permanent diligence asset.
3. Set a yield-adjusted reserve policy for the held book and apply it monthly, so revenue tracks economics instead of chargemaster.
4. Measure firm and funder concentration monthly, with a threshold that triggers a conversation, not a crisis.
5. Model hold-vs-sell at the portfolio level — the discount you accept for early cash is a financing rate; compare it to your actual cost of capital instead of your patience.

The Bottom Line

Florida taught imaging operators to think of PI revenue as a hybrid: statutory first dollars, attorney tail. Texas removes the first layer, and everything the hybrid structure was quietly absorbing — the working-capital drag, the valuation question on every receivable, the funder relationships — lands on the operator's books at full weight.

We serve multi-center imaging groups in both states, which is precisely why the difference is visible to us in the numbers rather than the marketing copy. If you operate imaging in Texas and your financial reporting still treats LOP paper as ordinary A/R at face value, the gap between your books and your business is wide enough to matter — and it's measurable.